title: Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy.
authors.forename: Rubens C
authors.initials: RC
authors.lastname: Siqueira
authors.forename: Rogério A
authors.initials: RA
authors.lastname: Costa
authors.forename: Ingrid U
authors.initials: IU
authors.lastname: Scott
authors.forename: Léssia P
authors.initials: LP
authors.lastname: Cintra
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Jorge
mesh_terms: D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008297:Male; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab